The blue cross blue shield assessment technology review: Summary of findings

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 3 SPEC. ISS., 2005, Pages 423-431

  Bennett, Charles L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Erythropoietin; Hemoglobin; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN DETERMINATION; HUMAN; LOW DRUG DOSE; META ANALYSIS; NATIONAL HEALTH INSURANCE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW;

EID: 15844390402     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.019     Document Type: Review

References (11)

1. D. Faulds E.M. Sorkin Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis Drugs 38 1989 863-899
2. J.W. Eschbach M.R. Kelly N.R. Haley R.I. Abels J.W. Adamson Treatment of the anemia of progressive renal failure with recombinant human erythropoietin N Engl J Med 321 1989 158-163
3. N. Muirhead J. Bargman E. Burgess K.K. Jindal A. Levin et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin Am J Kidney Dis 26 1995 S1-S24
4. J. Seidenfeld M. Piper C. Flamm et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials J Natl Cancer Inst 93 2001 1204-1214
5. J.D. Rizzo J. Seidenfeld M. Piper N. Aronson A. Lichtin et al. Erythropoietin: A paradigm for the development of practice guidelines Hematology (Am Soc Hematol Educ Program) 2001 10-30
6. T.J. Littlewood The impact of hemoglobin levels on treatment outcomes in patients with cancer Semin Oncol 28 2001 49-53
7. Aronson N, Seidenfeld J, Piper M, Flamm RC, Hasselblad V. Use of Erythropoietin in Oncology. Evidence Report/Technology Assessment No. 30. Prepared by the Blue Cross and Blue Shield Association Evidence-based Practice Center under Contract No. 290-97-0015. AHRQ Publ No. 01-E009. Rockville (MD): Agency for Healthcare Research and Quality; June 2001. http://www.ahrq.gov/.2001. Agency for Healthcare Research and Quality, US Department of Health and Human Services, 2101 East Jefferson Street, Rockville, MD 20852. Ref Type: Electronic Citation
8. N. Thatcher E.S. De Campos D.R. Bell et al.Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer Br J Cancer 80 1999 396-402
9. T.J. Littlewood E. Bajetta J.W. Nortier E. Vercammen B. Rapoport Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865-2874
10. S.D. Ross K. Fahrbach D. Frame R. Scheye J.E. Connelly et al. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review Clin Ther 25 2003 1786-1805
11. M. Hedenus M. Adriansson J. San Miguel et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study Br J Haematol 122 2003 394-403